表紙
市場調査レポート

EpiCast Report:アトピー性皮膚炎の疫学的予測

EpiCast Report: Atopic Dermatitis - Epidemiology Forecast to 2024

発行 GlobalData 商品コード 274740
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
EpiCast Report:アトピー性皮膚炎の疫学的予測 EpiCast Report: Atopic Dermatitis - Epidemiology Forecast to 2024
出版日: 2015年10月06日 ページ情報: 英文 42 Pages
概要

アトピー性皮膚炎(アトピー性湿疹)は、慢性的・再発的な皮膚疾患であることから、世界の保健衛生上の大きな懸念事項となっていますが、特に幼児の有病率が10〜20%(成人は1〜2%)と高くなっています。世界の主要9ヶ国の有病者数は、2014年には6,628万人、2024年には6,763万人に達すると予想されています。

当レポートでは、世界の主要国におけるアトピーせー皮膚炎の発症状況と今後の見通しについて分析し、疾患の特徴や、現在の有病者の発症状況、今後10年間の有病件数の予測値などを調査・推計して、その結果をお届けいたします。

第1章 目次

第2章 イントロダクション

  • 概要
  • 関連調査
  • 近刊の調査

第3章 疫学

  • 疾患の背景
  • リスク要因と共存症
    • リスク要因
      • 10歳以下の児童では、アトピー性皮膚炎の発症の可能性が3倍高くなる傾向にある
      • 家族歴;両親のどちらかに家族歴がある場合には、アトピー性皮膚炎の発症の可能性は4、両親ともある場合は6倍高くなる
      • 食品および環境におけるアレルゲンは、アトピー性皮膚炎の発症リスクを高める
      • 少なくとも生後3か月間母乳保育すれば、乳児をアトピー性皮膚炎から保護できる
    • 共存症
      • ぜんそく・アレルギー性鼻炎・アレルギー性結膜炎は、アトピー性皮膚炎と併発しやすい
      • アトピー性皮膚炎の患者は、精神疾患を発症する可能性が高くなる
  • 世界各国の動向
    • 米国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • 英国
    • 日本
    • 中国
    • インド
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法
  • アトピー性皮膚炎の疫学的予測(今後10年間分)
    • アトピー性皮膚炎の生涯有病者数
    • アトピー性皮膚炎の生涯有病者数:年齢別
    • アトピー性皮膚炎の生涯有病者数:男女別
    • 年齢調整済みの生涯有病者数
    • 生涯有病者数の内訳:重症度別
  • 考察
    • 疫学的傾向に関する結論
    • 分析の限界
    • 分析の強み

第4章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER089-15

Atopic dermatitis or atopic eczema is the most common type of eczema. Atopic dermatitis is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. Though the condition affects people of all ages, it is primarily common among infants and children. Risk factors for atopic dermatitis are broadly classified as modifiable and non-modifiable. Modifiable risk factors include inhalant allergens, food allergens, and newborns not being exclusively breastfed; non-modifiable risk factors include young age and genetics or heritability. In addition, the most common comorbidities associated with the atopic dermatitis such as atopic disorders and psychological disorders contribute significantly to the clinical occurrence of atopic dermatitis.

GlobalData epidemiologists forecast that the one-year total prevalent cases of atopic dermatitis in the 9MM will increase from 66,289,178 cases in 2014 to 67,630,097 cases in 2024 with an annual growth rate (AGR) of 0.20%. In the 9MM, India will have the highest number of one-year total prevalent cases of atopic dermatitis with 23,496,094 cases in 2024, followed by the US and China.

GlobalData epidemiologists forecast the prevalent cases of atopic dermatitis in the 9MM from 2014-2024 using country-specific studies that provided one-year total prevalence of atopic dermatitis in these markets obtained through symptom-based surveys. Furthermore, GlobalData epidemiologists selected nationally representative studies that provided data on distribution of atopic dermatitis severity in the 9MM. Moreover, GlobalData epidemiologists made sure that the selected nationally representative and country-specific studies assessed the atopic dermatitis prevalence, based on active symptoms during the past year in these markets.

Scope

  • The Atopic Dermatitis EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for atopic dermatitis in the nine major markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, China, and India). It includes a 10-year epidemiological forecast of the one-year prevalent cases of atopic dermatitis segmented by sex, age (in one-year increments beginning at 0 and ending at 19 years and also in five-year increments beginning at 20 years and ending at =85 years), and severity in these markets.
  • The Atopic Dermatitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The Atopic Dermatitis EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global atopic dermatitis market.
  • Quantify patient populations in the global atopic dermatitis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for atopic dermatitis therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. France
    • 3.3.3. Germany
    • 3.3.4. Italy
    • 3.3.5. Spain
    • 3.3.6. UK
    • 3.3.7. Japan
    • 3.3.8. China
    • 3.3.9. India
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Atopic Dermatitis (2014-2024)
    • 3.5.1. One-Year Total Prevalent Cases of Atopic Dermatitis
    • 3.5.2. Age-Specific One-Year Total Prevalent Cases of Atopic Dermatitis
    • 3.5.3. Sex-Specific One-Year Total Prevalent Cases of Atopic Dermatitis
    • 3.5.4. Age-Standardized One-Year Total Prevalence of Atopic Dermatitis
    • 3.5.5. One-Year Total Prevalent Cases of Atopic Dermatitis by Severity
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities of Atopic Dermatitis
  • Table 2: Diagnostic Criteria for Atopic Dermatitis
  • Table 3: The Hanifin and Rajka Diagnostic Criteria for Atopic Dermatitis
  • Table 4: 9MM, Sources of Epidemiological Data Used for the Forecast for the One-Year Total Prevalent Cases of Atopic Dermatitis
  • Table 5: 9MM, Sources of Epidemiological Data Used for the Segmentation of One-Year Total Prevalent Cases of Atopic Dermatitis by Severity
  • Table 6: 9MM, One-Year Total Prevalent Cases of Atopic Dermatitis, All Ages, Both Sexes, N, 2014-2024
  • Table 7: 9MM, One-Year Total Prevalent Cases of Atopic Dermatitis, by Age Group, Both Sexes, N, (Row %), 2014
  • Table 8: 9MM, One-Year Total Prevalent Cases of Atopic Dermatitis, by Sex, All Ages, N (Row %), 2014
  • Table 9: 9MM, One-Year Total Prevalent Cases of Atopic Dermatitis by Severity, All Ages, Both Sexes, N (Row %), 2014

List of Figures

  • Figure 1: 9MM, One-Year Total Prevalent Cases of Atopic Dermatitis, All Ages, Both Sexes, N, 2014-2024
  • Figure 2: 9MM, One-Year Total Prevalent Cases of Atopic Dermatitis, by Age Group, Both Sexes, N, 2014
  • Figure 3: 9MM, One-Year Total Prevalent Cases of Atopic Dermatitis, by Sex, All Ages, N, 2014
  • Figure 4: 9MM, Age-Standardized One-Year Total Prevalence (%) of Atopic Dermatitis, All Ages, Both Sexes, 2014
  • Figure 5: 9MM, One-Year Total Prevalent Cases of Atopic Dermatitis by Severity, All Ages, Both Sexes, N, 2014
Back to Top